-
Mashup Score: 3
Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel. Published February 23, 2024. (Webinar Video Proceedings) TARGET AUDIENCE This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of hepatobiliary cancers. LEARNING OBJECTIVES Interrogate recently presented trial results establishing the benefit of anti-PD-L1 antibody therapy in combination with anti-VEGF therapy as adjuvant treatment for patients with hepatocellul
Source: m.researchtopractice.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 4
Featuring perspectives from Dr Stephanie L Graff and Dr Erica Mayer. Published January 31, 2024. (Webinar Video Proceedings) TARGET AUDIENCE This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer. LEARNING OBJECTIVES Implement a long-term clinical plan for the management of localized hormone receptor (HR)-positive, HER2-negative breast cancer, accounting for newly presented clinical
Source: m.researchtopractice.comCategories: General Medicine News, Hem/OncsTweet-
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer (Webinar Video Proceedings) | Research To Practice @elmayermd #bcsm https://t.co/Q0RBog4LJQ
-
-
Mashup Score: 2Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology | Research To Practice - 2 year(s) ago
Join us on Wednesday, April 19th for this CME/MOC-accredited webinar 5:00 PM – 6:00 PM ET Faculty Pashtoon M Kasi, MD, MS Director, Colon Cancer Research Director, Liquid Biopsy Research Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine Englander Institute for Precision Medicine Division of Hematology and Medical Oncology NewYork-Presbyterian…
Source: m.researchtopractice.comCategories: Hem/Oncs, Latest HeadlinesTweet-
👇🏾Live webinar tomorrow📺 🗓️Wednesday April 19, 2023 🕔5-6 PM ET 🆓Registration Live CME/MOC #ColorectalCancer #CRCSM 💡We will discuss •Current Management •Promising Investigational Strategies #PrecisionMedicine #ctDNA @OncoAlert @DrNeilLove https://t.co/h1I1PouCVY https://t.co/c62LjCyMXr
-
-
Mashup Score: 1Oncology Today with Dr Neil Love: Advances in Gynecologic Cancers from the 2022 ASCO Annual Meeting (Video Lecture) | Research To Practice - 3 year(s) ago
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Audio Interview: Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent…
Source: m.researchtopractice.comCategories: Hematologists1, Latest HeadlinesTweet-
RT @GynCancerMD: https://t.co/7O7kF84cve always great to have opportunity to work with Dr. Neil Love and hos team at Research to Practice.…
-
-
Mashup Score: 2
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent…
Source: m.researchtopractice.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Great to talk about all things IO & lung cancer with @DrNeilLove Check out the podcast link for a case based discussion on: - periop IO in nsclc - IO in mNSCLC - IO in meso - IO in sclc https://t.co/tjbxc3xjl9 @CancerCentreIre @RCSI_Research @HopkinsThoracic @IrishLungCancer https://t.co/qus0f7rp4G
-
Dr Neil Love was joined by Dr Ahmed Omar Kaseb and Prof Arndt Vogel to discuss current and emerging therapies for patients with hepatocellular carcinoma and biliary tract cancers. This event is designated for a maximum of 1.75 AMA PRA Category 1 Credits. https://t.co/jrCfJUkcU3 https://t.co/zjVEErsgI6